Professor Charles Ramassamy and his postdoctoral researcher Mohamed Haddad at Institut national de la recherche scientifique (INRS), in collaboration with scientists from Université de Montréal, McGill University, and Université du Québec à Montréal (UQAM), believe that tannic acid plays a role in inhibiting three important molecular pathways involved in the SARS-CoV-2 infection. Their work was published recently in the International Journal of Molecular Sciences (IJMS).
Using a multidisciplinary approach, the teams showed that tannic acid inhibits the viral protein (RBD) of the British variant of SARS-CoV-2 from binding to its biological target, the ACE2 receptor. This receptor, which is found on the surface of many cells in the body, allows the virus to latch on and infect them. "Tannic acid binds to the RBD protein and prevents it from binding to the ACE2 receptor," said Professor Ramassamy. He explained that in blocking the viral protein, tannic acid does not alter the physiological functions of ACE2 receptors, which have physiological functions in the body's respiratory, cardiovascular, and renal systems, among others.
His team further investigated the effects of tannic acid on other key mechanisms involved in SARS-CoV-2 infection downstream of the RBD-ACE2 bond. The team showed that this polyphenol can inhibit the activity of the enzyme that allows the virus to enter our cells (TMPRSS2), as well as the viral enzyme responsible for replicating the virus (3CLpro).
An alternative to antivirals
The effects of tannic acid on the RBD protein and these enzymes pave the way for further research on the entire virus in contact with human cells. If the beneficial properties are similar on a larger scale, tannic acid tablets or nasal spray could be envisaged as a means for preventing or blocking SARS-CoV-2 infection.
Tannic acid is a natural polyphenol found in many beverages such as red wine or tea, but in much lower quantities. Although they contain tannins, their consumption would not have any protective effects because of their low concentration of tannic acid.
"It would be less expensive than the antivirals currently on the market, and there would be fewer side effects because of the low toxicity of tannic acid and other polyphenols. In addition, tannic acid and its physiological derivatives have anti-inflammatory and antioxidant properties, both of which are beneficial if you are infected with SARS-CoV-2," said Professor Ramassamy.
The research builds on the teams' previous work on two other types of polyphenols—TGG and corilagin—and their interaction with a number of SARS-CoV-2 variants. The two compounds had similar beneficial effects, but were less effective than tannic acid.
About the study
The article "Molecular Interactions of Tannic Acid with Proteins Associated with SARS-CoV-2 Infectivity", by Mohamed Haddad, Roger Gaudreault, Gabriel Sasseville, Phuong Trang Nguyen, Hannah Wiebe, Theo G.M. van de Ven, Steve Bourgault, Normand Mousseau, and Charles Ramassamy, was published in the International Journal of Molecular Sciences on Febuary 27th 2022. The study received financial support from the Natural Sciences and Engineering Research Council of Canada (NSERC), the Institut sur la nutrition et les aliments fonctionnels (INAF) and Fonds de recherche du Québec - Nature et technologies (FQRNT).
About INRS
INRS is a university dedicated exclusively to graduate level research and training. Since its creation in 1969, INRS has played an active role in Québec's economic, social, and cultural development and is ranked first for research intensity in Québec. INRS is made up of four interdisciplinary research and training centres in Québec City, Montréal, Laval, and Varennes, with expertise in strategic sectors: Eau Terre Environnement, Énergie Matériaux Télécommunications, Urbanisation Culture Société, and Armand-Frappier Santé Biotechnologie. The INRS community includes more than 1,500 students, postdoctoral fellows, faculty members, and staff.
Source :
Audrey-Maude Vézina
Service des communications et des affaires publiques de l'INRS
418 254-2156
